NCT06729775 · University of Arizona
Disentangling the Role of Culture, Life Stage, and Information Design to Facilitate Equity in Data Report Back
What this study is about
There remains a need for novel research that facilitates RBRR in a manner that raises data and environmental health literacy (D/EHL) and supports communities striving for environmental health and structural change.
View original scientific description
There remains a need for novel research that facilitates RBRR in a manner that raises data and environmental health literacy (D/EHL) and supports communities striving for environmental health and structural change. Rooted in bioethics and building upon trusted and established long-term partnerships and leveraging existing datasets, the project goal is to create and pilot a national model of report back that is centered in the margins and engages diverse rural and urban EJ communities to ensure that RBRR reaches all populations in a manner tailored to their individual needs, including culture, life stage, language, and design.
Interventions
OTHER
Data report back preference by life span
Data report back preference by life span.
Primary outcome measures
Changes from baseline in the mean literacy and numeracy based on questionnaire responses.
Time frame: From enrollment to the end of treatment at 78 weeks
Likert scale where one is equivalent to "Disagree Very Strongly" and six is Agree Very Strongly.
Changes from baseline in the mean knowledge and awareness risks based on questionnaire responses.
Time frame: From enrollment to the end of treatment at 78 weeks
Likert scale where one is equivalent to "Disagree Very Strongly" and six is Agree Very Strongly.
Changes from baseline in the mean skills and self-efficacy based on questionnaire responses.
Time frame: From enrollment to the end of treatment at 78 weeks
Likert scale where one is equivalent to "Disagree Very Strongly" and six is Agree Very Strongly.
Changes from baseline in the mean environmental health engagement based on questionnaire responses.
Time frame: From enrollment to the end of treatment at 78 weeks
Likert scale where one is equivalent to "Disagree Very Strongly" and six is Agree Very Strongly.
Number of participants reporting themes related to literacy and numeracy.
Time frame: From enrollment to the end of treatment at 78 weeks
This is a qualitative analysis; words will be coded and analyzed to identify themes and sentiment's that arise in individual interviews and across all interviews and focus groups.
Number of participants reporting themes related to knowledge and awareness risks
Time frame: From enrollment to the end of treatment at 78 weeks
This is a qualitative analysis; words will be coded and analyzed to identify themes and sentiment's that arise in individual interviews and across all interviews and focus groups.
Number of participants reporting themes related to skills and self-efficacy
Time frame: From enrollment to the end of treatment at 78 weeks
This is a qualitative analysis; words will be coded and analyzed to identify themes and sentiment's that arise in individual interviews and across all interviews and focus groups.
Number of participants reporting themes related to environmental health engagement.
Time frame: From enrollment to the end of treatment at 78 weeks
This is a qualitative analysis; words will be coded and analyzed to identify themes and sentiment's that arise in individual interviews and across all interviews and focus groups.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Participants should live in Pinal county, Arizona, Gila county, Arizona, and Cuyahoga county, Ohio.
Exclusion criteria
- Individuals living outside of the partnering counties will not be eligible for participation.
Where
- Tucson, Arizona
Collaborators
National Institute of Environmental Health Sciences (NIEHS)
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Apr 8, 2025 · Source of record for eligibility and locations